Xenon Pharmaceuticals (NASDAQ:XENE) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.16), Fidelity Earnings reports.
Shares of NASDAQ:XENE traded down $0.16 during trading on Wednesday, hitting $9.81. 4,490 shares of the company’s stock traded hands, compared to its average volume of 145,876. Xenon Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $15.92. The company has a debt-to-equity ratio of 0.41, a current ratio of 20.83 and a quick ratio of 20.83. The stock has a market capitalization of $205.71 million, a PE ratio of -5.69 and a beta of 1.20.
Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub cut Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 22nd. Jefferies Financial Group reiterated a “buy” rating and set a $16.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday, August 10th. Finally, Stifel Nicolaus lifted their price objective on Xenon Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $14.33.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
Featured Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.